Malignant Mesothelioma brings together the most current diagnostic criteria and treatment plans from the world's leading experts on this rare but devastating cancer. The first edition was a critical and commercial success and this revision builds on that reputation. The editors have brought together the world's leading experts to fully explore the latest scientific breakthroughs in carcinogenesis, immunotherapy, potential vaccination strategies, and gene therapy. The clinical aspects of the book are equally strong, with thorough discussion of epidemiology, etiology, different clinical presentations, imaging (including interventional pulmonology), treatment of benign disease, strategies for multimodality treatment of malignant disease. Editors: Harvey I. Pass, M.D, Chief, Thoracic Surgery, New York University, New York, NY; Nicholas Vogelzang, M.D, Director, Nevada Cancer Institute, Las Vegas, NV; University of Chicago, Michele Carbone, M.D., Ph.D, Researcher and Director, Thoracic Oncology Program, Cancer Research Center of Hawaii, Honolulu, HI; and Anne S. Tsao, M.D, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.